Heart Diseases Clinical Trial
Official title:
Utility of Donor-Derived Cell-free DNA in Association With Gene-Expression Profiling (AlloMap®) in Heart Transplant Recipients (D-OAR)
Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in association with the measurement of AlloMap, a non-invasive gene expression test to aid in heart transplant management.
AlloMap Molecular Expression Testing is performed in a single laboratory, assessing the gene
expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). Per FDA
labeling, AlloMap Testing is "intended to aid in the identification of heart transplant
recipients with stable allograft function who have a low probability of moderate/severe acute
cellular rejection (ACR) at the time of testing in conjunction with standard clinical
assessment." AlloMap is the only non-invasive, blood test method recommended in the
International Society for Heart and Lung Transplantation (ISHLT) guidelines for surveillance
of heart transplant recipients for rejection. More than 52,000 commercial AlloMap tests from
more than 12,000 patients have been reported by the XDx Reference Laboratory in Brisbane,
California, which is certified under the Clinical Laboratory Improvement Amendment (CLIA) of
1988 and accredited by the College of American Pathologists.
In 2013, a registry study named OAR was initiated to follow long-term outcomes in allograft
recipients receiving commercial AlloMap testing for surveillance (NCT01833195). The current
objective is to enroll volunteers who are participating in the OAR registry(1) to
co-participate in this observational sub-study, named D-OAR, in order to study a new
biomarker, dd-cfDNA.
dd-cfDNA has been proposed as a marker for cellular injury caused by rejection(2, 3). Because
dd-cfDNA and the AlloMap test measure different signals in the blood, a combination of the
two approaches could be additive since AlloMap is a measure of host immune response and
dd-cfDNA monitors graft injury.
The dd-cfDNA measurement is intended for the quantitative detection of plasma dd-cfDNA as a %
of the total plasma cell-free DNA. Its utility as a surveillance tool in the management of
heart transplant recipients is being investigated.
This is an observational sub-study for subjects who are co-enrolled to participate in the
Outcomes AlloMap Registry (OAR). Prior to implementation of the amendment dated September 15,
2016, blood specimens were collected for assay of dd-cfDNA levels at each visit that occurred
for AlloMap testing, per the OAR Study. As stated in the OAR study, the regular surveillance
schedule for testing with AlloMap is determined by each participating center's standard of
care. After this protocol amendment, the existing patients will no longer have routine
dd-cfDNA specimens drawn to be paired with their standard of care AlloMap. The dd-cfDNA
specimen will be drawn only when the patient is scheduled for a for-cause biopsy. New
patients may be enrolled any time post-transplant as long as they have not had more than 1
prior AlloMap. These patients will also only undergo routine AlloMap testing as per
participating center's standard of care and dd-cfDNA specimen will be drawn when the patient
is scheduled for a for-cause biopsy. An AlloMap sample will be drawn for research use along
with the dd-cfDNA specimen at the time of the for-cause biopsy where the center's
infrastructure permits. An additional two follow-up dd-cfDNA specimens will be collected in
the patients that undergo a for-cause biopsy, and are being treated for rejection and/or
graft dysfunction, as per their standard of care schedule. The two follow-up visits will not
be paired with a research use AlloMap and will be performed within 8 weeks after the for
cause event. If a patient returns for another for-cause biopsy, the center may opt to collect
another research AlloMap and dd-cfDNA specimen, and two follow-up dd-cfDNA specimens.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624412 -
Different Intensities of Continuous Aerobic Exercises in Cardiac Rehab Phase 2
|
N/A | |
Completed |
NCT05563701 -
Evaluation of the LVivo Image Quality Scoring (IQS)
|
||
Recruiting |
NCT04561908 -
Transcatheter Microguidewire Drilling for Transseptal Left Atrial Access
|
N/A | |
Active, not recruiting |
NCT06190743 -
Perception of Cardiovascular Risk
|
||
Completed |
NCT04562636 -
Evaluating a Messaging Campaign in the United States
|
N/A | |
Completed |
NCT04580095 -
Artificial Intelligence for Improved Echocardiography
|
N/A | |
Recruiting |
NCT03277365 -
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
|
N/A | |
Active, not recruiting |
NCT05553106 -
Evaluation of Cognitive Status, Kinesiophobia, Physical Activity Level, and Functional Performance in Coronary Intensive Care
|
||
Completed |
NCT03429920 -
Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors
|
N/A | |
Recruiting |
NCT04390672 -
Multivessel TALENT
|
N/A | |
Enrolling by invitation |
NCT03314818 -
Natural History of Carotid Plaque as Determined by 3D Ultrasound
|
N/A | |
Withdrawn |
NCT03289104 -
Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX
|
N/A | |
Completed |
NCT02917213 -
Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
|
||
Completed |
NCT02046902 -
Developing and Testing a Personalized Evidence-based Shared Decision-making Tool for Stent Selection
|
||
Completed |
NCT01909349 -
Web-based Aftercare Intervention for Cardiac Patients
|
N/A | |
Completed |
NCT01944254 -
The Precision of Pulmonary Artery Cardiac Output-measurements in Spontaneously Breathing Patients
|
N/A | |
Recruiting |
NCT01457586 -
Hemoderivative Imputable Complications in Initial Uncomplicated Heart Surgery
|
Phase 4 | |
Recruiting |
NCT01207167 -
Mediators of Atherosclerosis in South Asians Living in America
|
||
Recruiting |
NCT01541163 -
Heart and Ischemic STrOke Relationship studY
|
N/A | |
Terminated |
NCT00968383 -
Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment
|
N/A |